On August 25, Electromed (NASDAQ:ELMD) reported fiscal fourth-quarter results that extended a streak few small-cap medical device companies can claim: fifteen consecutive quarters of year-over-year revenue and profit growth. Net revenue hit a record $19.4 million, up 11.6% from a year earlier, and diluted earnings per share climbed to $0.39 from $0.25. Those headline numbers look clean, but they arrive alongside a leadership change and a hospital business moving in the opposite direction, which makes the quarter more complicated than the growth streak suggests.
Fifteen Straight Quarters Of Proof
Home care is still the whole story here. Home care revenue reached $17.7 million in the quarter, up 15.2% year over year, and for the full fiscal year it grew 16.3% to $66.6 million. That growth is coming from efficiency, not just headcount: on an annualized basis, home care revenue worked out to $1,145,000 per rep, above the company’s own target range of $1 million to $1.1 million. Electromed ended the year with 64 direct sales reps and is targeting 67 filled territories for fiscal 2027, including two hospital account liaisons meant to catch patients as they move from acute care into home-based therapy.
The addressable market behind that growth still looks large. Management estimates roughly 1 million people in the U.S. carry a bronchiectasis diagnosis, yet only about 16% currently use high-frequency chest wall oscillation therapy, leaving close to 800,000 diagnosed patients untreated, plus more than 4 million additional people who may have the condition without a diagnosis at all. Payer access has kept pace with that opportunity.
Electromed closed the fiscal year with 87% of US covered lives under contract after signing 40 new payer agreements and adding 6 million covered lives. Its Smart Order e-prescribing tool handled 45% of fourth-quarter orders and shipped them noticeably faster than fax submissions, which matters as CMS rules phase out fax-based ordering by May 2028. All of this sits on a debt-free balance sheet, with cash growing to $20.5 million even after $3.9 million in share repurchases during the year.
Cracks Beneath The Surface
The weaker spots are easy to miss next to those numbers. Hospital revenue fell 29% in the fourth quarter, which CEO James Cunniff attributed to a sales cycle that is “inherently less predictable than our other channels.” The distributor channel grew just 2% in the quarter, and combined, the non-home care business grew only 6.7% for the full year versus 16.3% in home care, meaning nearly all of Electromed’s growth is coming from one channel. SG&A expenses rose 8.7% to $42.7 million for the year, driven mainly by higher sales, marketing, and reimbursement compensation, and accounts receivable climbed to $29.8 million from $24.7 million as the business scaled up.
Operating cash flow actually declined to $9.7 million for fiscal 2026 from $11.4 million a year earlier, even as net income rose sharply, a gap worth watching if it persists. On top of the operating picture sits a leadership transition: Cunniff announced plans to retire as CEO with an expected timing of April 2027, and no successor has been named yet. Research and development spending, meanwhile, remains modest at $1.3 million for the year, a small figure for a company whose long-term growth depends on expanding its product line and adding connectivity features.
Wall Street Isn’t Paying Attention
Hedge fund ownership of Electromed rose to 13 funds in the most recent quarter from 12 the quarter before, a modest uptick in institutional interest. Short sellers have shown little appetite to bet against the stock, with short interest at just 1.12% of float. As of September 2, the stock trades at a forward price-to-earnings ratio of 7.81, a multiple that looks low next to the double-digit revenue growth and expanding margins management just reported.
What Happens Next
Electromed’s fifteenth straight quarter of growth is a real achievement, built on a home care sales model that keeps getting more efficient and a bronchiectasis market that remains largely untapped. But the hospital channel’s decline, the reliance on a single growth engine, and an unresolved leadership transition add genuine uncertainty to a story that has otherwise looked clean. For the growth case to hold, the expanded sales force and new payer contracts need to keep translating into home care gains at the current pace.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Follow Insider Monkey on Google News.
Hedge Fund Resource Center